Atara Biotherapeutics Inc. (NASDAQ:ATRA) marked $4.16 per share on Monday, up from a previous closing price of $3.89. While Atara Biotherapeutics Inc. has overperformed by 6.94%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATRA fell by -70.93%, with highs and lows ranging from $16.35 to $2.83, whereas the simple moving average fell by -15.34% in the last 200 days.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
On July 20, 2022, Citigroup Downgraded Atara Biotherapeutics Inc. (NASDAQ: ATRA) to Sell. A report published by Stifel on July 13, 2022, Downgraded its rating to ‘Hold’ for ATRA. JP Morgan also Downgraded ATRA shares as ‘Neutral’, setting a target price of $10 on the company’s shares in a report dated July 13, 2022. Citigroup May 10, 2022d the rating to Neutral on May 10, 2022, and set its price target from $15 to $8. JP Morgan May 13, 2021d its ‘Neutral’ rating to ‘Overweight’ for ATRA, as published in its report on May 13, 2021. Citigroup’s report from December 09, 2020 suggests a price prediction of $27 for ATRA shares, giving the stock a ‘Neutral’ rating. H.C. Wainwright also rated the stock as ‘Buy’.
Analysis of Atara Biotherapeutics Inc. (ATRA)
Further, the quarter-over-quarter decrease in sales is -16.70%, showing a negative trend in the upcoming months.
In order to gain a clear picture of Atara Biotherapeutics Inc.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -104.20% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.90, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.44M can be a very valuable indicator of volatility for ATRA stock. On a monthly basis, the volatility of the stock is set at 7.55%, whereas on a weekly basis, it is put at 7.65%, with a gain of 6.94% over the past seven days. Furthermore, long-term investors anticipate a median target price of $18.88, showing growth from the present price of $4.16, which can serve as yet another indication of whether ATRA is worth investing in or should be passed over.
How Do You Analyze Atara Biotherapeutics Inc. Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.50%. This can enable you to see the extent to which executives own the company’s stock.
Are institutional investors increasing their holdings in ATRA shares?
The recent increase in stakes in ATRA appears to be a result of several institutional investors and hedge funds increasing their positions. Wasatch Advisors, Inc.’s position in ATRA has increased by 58.70% in the first quarter. The company now owns 8,136,363 shares of the stock, with a value of $26.69 million, following the purchase of 3,009,640 additional shares during the last quarter. During the last quarter, the company picked up 0 additional shares for a total stake of worth $26.65 million, bringing number of shares owned by the company to 8,123,616.
At the end of the first quarter, BlackRock Fund Advisors increased its ATRA holdings by 0.82% and now holds 6.95 million ATRA shares valued at $22.81 million with the added 56773.0 shares during the period.
